Iovance Biotherapeutics, Inc. IOVA NASDAQ

Iovance Biotherapeutics, Inc. (IOVA) generated $-302.41M in operating cash flow for fiscal year 2025. After capital expenditures of $33.84M, free cash flow was $-336.24M.

Free cash flow margin was -127.6% of revenue. Cash conversion ratio was 0.77x, suggesting some earnings are non-cash.

Criteria supported by this page:

• HEALTH (100/100, Pass) — demonstrate the company can comfortably service its debt
• MOAT (70/100, Pass) — $-336.24M (-127.6% FCF margin) supports a durable competitive advantage
• INCOME (10/100) — Cash conversion ratio was 0.77x suggests some earnings are non-cash items

Overall SharesGrow Score: 50/100 with 3/7 criteria passed.